Pediatric Neurology
Volume 29, Issue 3 , Pages 203-206 , September 2003

Oral baclofen in cerebral palsy: possible seizure potentiation?

  • Donna E Hansel, MD, PhD

      Affiliations

    • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • ,
  • Christian R.W Hansel, PhD

      Affiliations

    • Department of Neuroscience, Erasmus Medical Center, Rotterdam, Netherlands
    • ,
  • Michael K Shindle, BA

      Affiliations

    • Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • ,
  • Elsie M Reinhardt, MSN, PNP

      Affiliations

    • Kennedy Krieger Institute, Baltimore, Maryland, USA
    • ,
  • LaVerne Madden, BSN, RN

      Affiliations

    • Kennedy Krieger Institute, Baltimore, Maryland, USA
    • ,
  • Eric B Levey, MD

      Affiliations

    • Kennedy Krieger Institute, Baltimore, Maryland, USA
    • Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • ,
  • Michael V Johnston, MD

      Affiliations

    • Kennedy Krieger Institute, Baltimore, Maryland, USA
    • Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • ,
  • Alexander H Hoon Jr., MD, MPH

      Affiliations

    • Kennedy Krieger Institute, Baltimore, Maryland, USA
    • Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • Corresponding Author InformationCommunications should be addressed to: Dr. Hoon; Division of Neurology and Developmental Medicine; Kennedy Krieger Institute; 707 North Broadway; Baltimore, MD 21205, USA.

Received 26 November 2002 ,Accepted 3 March 2003.

References 

  1. Brandt NJ, Gregersen N, Christensen E, Gron IH, Rasmussen K. Treatment of glutaryl CoA dehydrogenase deficiency (glutaric aciduria). Experience with diet, riboflavin and GABA analogue. J Pediatr. 1979;94:669–673
  2. Penn RD, Kroin JS. Continuous intrathecal baclofen for severe spasticity. Lancet. 1985;2:125–127
  3. Saltuari L, Schmutzhard E, Kofler M, Baumgartner H, Aichner F, Gerstenbrand F. Intrathecal baclofen for intractable spasticity due to severe brain injury. Lancet 89;2:503-4
  4. Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA. 1991;265:1418–1422
  5. Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol. 1996;11:77–83
  6. Gerszten PC, Albright AL, Barry MJ. Effect of ambulation of continuous intrathecal baclofen. Pediatr Neurosurg. 1997;27:40–44
  7. Petersen MC, Palmer FB. Advances in prevention and treatment of cerebral palsy. Ment Retard Dev Disabil Res Rev. 2001;7:30–37
  8. Krach LE. Pharmacotherapy of spasticity (Oral medications and intrathecal baclofen). J Child Neurol. 2001;16:31–36
  9. Paisley S, Beard S, Hunn A, Wight J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis (A systematic review). Mult Scler. 2002;8:319–329
  10. Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol. 1992;15:276–288
  11. Walker RH, Danisi FO, Swope DM, Goodman RR, Germano IM, Brin MF. Intrathecal baclofen for dystonia (Benefits and complications during six years of experience). Mov Disord. 2000;15:1242–1247
  12. Albright AL, Barry MJ, Shafton DH, Ferson SS. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol. 2002;43:652–657
  13. Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy (Annotation). Dev Med Child Neurol. 2000;42:634–645
  14. Gerszten PC, Albright AL, Johnstone GF. Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy. J Neurosurg. 1998;88:1009–1013
  15. Muller H, Zierski J, Dralle D, Kraub D, Mark-Schler E. Pharmacokinetics of intrathecal baclofen. In:  Muller H,  Zierski J,  Penn R editor. Local-spinal therapy of spasticity. New York: Springer-Verlag; 1988;p. 223–226
  16. Albright AL, Shultz BL. Plasma baclofen levels in children receiving continuous intrathecal baclofen infusion. J Child Neurol. 1999;14:408–409
  17. Goulden KJ, Shinnar S, Koller H, Katz M, Richardson SA. Epilepsy in children with mental retardation (A cohort study). Epilepsia. 1991;32:690–697
  18. D’Amelio M, Shinnar S, Hauser WA. Epilepsy in children with mental retardation and cerebral palsy. In:  Devinsky O,  Westbrook LE editor. Epilepsy and developmental disabilities. Woburn, MA: Butterworth-Heinemann; 2002;p. 3–16
  19. Wallace SJ. Epilepsy in cerebral palsy (Annotation). Dev Med Child Neurol. 2001;43:713–717
  20. Nevo Y, Shinnar S, Samuel E, et al.  Unprovoked seizures and developmental disabilities (Clinical characteristics of children referred to a child development center). Pediatr Neurol. 1995;13:235–241
  21. Kofler M, Auturo Leis A. Prolonged seizure activity after baclofen withdrawal. Neurology. 1992;42:697–698
  22. Perry HE, Wright RO, Shannon MW, Woolf AD. Baclofen overdose (Drug experimentation in a group of adolescents). Pediatrics. 1998;101:1045–1048
  23. Rush JM, Gibberd FB. Baclofen-induced epilepsy. J R Soc Med. 1990;83:115–116
  24. Zak R, Solomon G, Petito F, Labar D. Baclofen-induced generalized nonconvulsive status epilepticus. Ann Neurol. 1994;36:113–114
  25. Kofler M, Kronenberg MF, Rifici C, Saltuari L, Bauer G. Epileptic seizures associated with intrathecal baclofen application. Neurology. 1994;44:25–27
  26. Terrence CF, Fromm GH, Roussan MS. Baclofen (Its effect on seizure frequency). Arch Neurol. 1983;40:28–30
  27. Zafeirious DI, Kontopoulos EE, Tsikoulas I. Characteristics and prognosis of epilepsy in children with cerebral palsy. J Child Neurol. 1999;14:289–294
  28. Velisek L, Veliskova J, Ptachewich Y, Ortiz J, Shinnar S, Moshe SL. Age-dependent effects of gamma-aminobutyric acid agents on flurothyl seizures. Epilepsia. 1995;36:636–643
  29. Kubova H, Haugvicova R, Mares P. Moderate anticonvulsant action of baclofen does not change during development. Biol Neonate. 1996;69:405–412
  30. Bowery N. GABAB receptors and their significance in mammalian pharmacology. Trends Pharmacol Sci. 1989;10:401–407
  31. Schwartzkroin PA. Pathophysiology of cortical synapses and circuits. In:  Gutnick MJ,  Mody I editor. The cortical neuron. New York: Oxford University Press; 1995;p. 276–292
  32. Walker MC, Kullmann DM. Febrile convulsions (A “benign” condition?). Nat Med. 1999;5:871–872
  33. Cobb SR, Buhl EH, Halasy K, Paulsen O, Somogyi P. Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons. Nature. 1995;378:75–78
  34. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 1999;40:S2–10
  35. Thompson SM, Gähwiler BH. Comparison of the actions of baclofen at pre- and postsynaptic receptors in the rat hippocampus in vitro. J Physiol. 1992;451:329–345
  36. Thompson SM, Capogna M, Scanziani M. Presynaptic inhibition in the hippocampus. Trends Neurosci. 1993;16:222–227
  37. Burgard EC, Sarvey JM. Long-lasting potentiation and epileptiform activity produced by GABAB receptor activation in the dentate gyrus of rat hippocampal slice. J Neurosci. 1991;11:1198–1209
  38. Harrison NL. On the presynaptic action of baclofen at inhibitory synapses between cultured rat hippocampal neurones. J Physiol. 1990;422:433–446
  39. Xiong Z-Q, Stringer JL. Effects of postsynaptic GABAB receptor activation on epileptiform activity in hippocampal slices. Neuropharmacology. 2001;40:131–138
  40. Mott DD, Bragdon AC, Lewis DV, Wilson WA. Baclofen has a proepileptic effect in the rat dentate gyrus. J Pharmacol Exp Ther. 1989;249:721–725
  41. Sokal DM, Large CH. The effects of GABAB receptor activation on spontaneous and evoked activity in the dentate gyrus of kainic acid-treated rats. Neuropharmacology. 2001;40:193–202

PII: S0887-8994(03)00208-X

doi: 10.1016/S0887-8994(03)00208-X

Pediatric Neurology
Volume 29, Issue 3 , Pages 203-206 , September 2003

Article Tools

* Image Usage & Resolution